MY126358A - Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs - Google Patents

Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Info

Publication number
MY126358A
MY126358A MYPI97001186A MYPI9701186A MY126358A MY 126358 A MY126358 A MY 126358A MY PI97001186 A MYPI97001186 A MY PI97001186A MY PI9701186 A MYPI9701186 A MY PI9701186A MY 126358 A MY126358 A MY 126358A
Authority
MY
Malaysia
Prior art keywords
tpgs
vitamin
compositions
water soluble
tocopherol derivative
Prior art date
Application number
MYPI97001186A
Other languages
English (en)
Inventor
Arup K Roy
Lloyd Gary Tillman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY126358A publication Critical patent/MY126358A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI97001186A 1996-03-22 1997-03-20 Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs MY126358A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MY126358A true MY126358A (en) 2006-09-29

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97001186A MY126358A (en) 1996-03-22 1997-03-20 Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Country Status (12)

Country Link
JP (1) JP3117726B2 (pl)
AR (1) AR006345A1 (pl)
BG (1) BG64457B1 (pl)
CO (1) CO4790151A1 (pl)
HU (1) HU228026B1 (pl)
ID (1) ID16781A (pl)
IL (1) IL126185A (pl)
MY (1) MY126358A (pl)
OA (1) OA10880A (pl)
PL (1) PL187919B1 (pl)
TW (1) TW455491B (pl)
WO (1) WO1997035587A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (es) * 1997-12-04 2000-10-16 Univ Granada Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
EP1354587A1 (en) * 2000-12-22 2003-10-22 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
CA2578356C (en) * 2004-09-24 2013-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials
CN101031284A (zh) * 2004-09-30 2007-09-05 伊斯曼化学公司 使亲脂性药物增溶而无显著外排抑制作用的含有维生素e tpgs分子的药物制剂和该制剂的用途
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (ar) * 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1677092A (en) * 1991-03-20 1992-10-21 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
IL103613A (en) * 1991-11-08 1999-05-09 Merck & Co Inc VIH protease inhibitors, and the process of preparing intermediates and pharmaceutical preparations containing them.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ATE143262T1 (de) * 1992-12-29 1996-10-15 Abbott Lab Inhibitoren der retroviralen protease
AU6087194A (en) * 1993-01-15 1994-08-15 Agouron Pharmaceuticals, Inc. Hiv protease inhibitors
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
NZ278201A (en) * 1993-12-15 1998-01-26 Merck & Co Inc Bicyclic heterocyclically substituted piperazine derivatives as hiv protease inhibitors
EP0749421B1 (en) * 1994-03-07 1999-09-15 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0825849A1 (en) * 1995-05-19 1998-03-04 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
TW455491B (en) 2001-09-21
PL328916A1 (en) 1999-03-01
HU228026B1 (en) 2012-08-28
WO1997035587A1 (en) 1997-10-02
IL126185A (en) 2003-05-29
BG64457B1 (bg) 2005-03-31
HUP9901887A2 (hu) 1999-12-28
JP2000500504A (ja) 2000-01-18
CO4790151A1 (es) 1999-05-31
AR006345A1 (es) 1999-08-25
OA10880A (en) 2001-10-11
JP3117726B2 (ja) 2000-12-18
PL187919B1 (pl) 2004-11-30
HUP9901887A3 (en) 2000-02-28
IL126185A0 (en) 1999-05-09
BG102838A (en) 1999-09-30
ID16781A (id) 1997-11-13

Similar Documents

Publication Publication Date Title
MY126358A (en) Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ES2178674T3 (es) Composiciones de tocoferol destinadas a la administracion de agentes biologicamente activos.
ATE533472T1 (de) Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute
HK1012566A1 (en) Pharmaceutical formulations in form of thixotropic gel
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
IL114193A0 (en) Ophthalmic pharmaceutical compositions
PA8575701A1 (es) Preparaciones acidas de insulina con estabilidad mejorada
MXPA05002814A (es) Formulacion para agentes lipofilicos.
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
GEP20053473B (en) High Potency Dihydroergotamine Compositions
TR200001977T2 (tr) Lipofilik glukokortikosteroit içeren miseller ihtiva eden bileşimler
WO2001038303A3 (fr) Analogues de la vitamine d
HUP0100539A2 (hu) D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
HUP0004375A2 (hu) Azelainsavat tartalmazó kompozíció
CA2028629A1 (en) Antiandrogenically-effective pharmaceutical compositions
HUP0304077A2 (hu) A bőr öregedése elleni gyógyászati és kozmetikai készítmények
UA10208A (uk) Дерматологічний косметичний засіб
PA8449301A1 (es) Composiciones farmaceuticas
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
EP1429723A4 (en) TREATMENT EFFECTS OF EXCESSIVE REACTIVE OXYGEN SPECIES
DE69800804D1 (de) Halbfeste pharmazeutische zubereitungen enthaltend dexketoprofen-trometamol
CA2249336A1 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs
AU3739500A (en) Protease resistant flint analogs